Two medicine make up almost two-thirds of Eli Lilly‘s (NYSE: LLY) high line, producing round $12.8 billion in revenues within the first quarter of 2026. The 2 medicine, Mounjaro and Zepbound, are rising strongly as nicely, with gross sales up 125% and 80% 12 months over 12 months, respectively, within the first quarter. So why ought to traders care that Eli Lilly simply spent $3.8 billion to purchase three vaccine-focused corporations?
The market will get myopically centered at occasions
To make the Mounjaro and Zepbound story much more fascinating, these two medicines are each GLP-1 weight-loss medicine. It is a sizzling new class within the pharmaceutical sector the place Eli Lilly is presently the class chief. Basically, the inventory more and more appears like a one-tick pony, and traders are blissful about it, noting that the price-to-earnings ratio is a lofty 39x. The typical pharmaceutical inventory has a P/E of round 24x.
Will AI create the world’s first trillionaire? Our workforce simply launched a report on the one little-known firm, known as an “Indispensable Monopoly” offering the vital know-how Nvidia and Intel each want. Proceed »
The $3.8 billion Eli Lilly is spending to purchase Curevo, LimmaTech Biologics AG, and Vaccine Firm will shortly construct its presence within the infectious illness house. Which, for now, will likely be inconsequential to its enterprise. Within the close to time period, traders will likely be watching Mounjaro, Zepbound, and the corporate’s newly launched GLP-1 tablet, Foundayo. However the huge story that traders could also be lacking is vital.
Eli Lilly is aware of the drug enterprise nicely sufficient to organize forward
The corporate’s GLP-1 portfolio is a crucial story, however it’s one which comes with an finish date. That is simply how the pharmaceutical business works, since medicine have time-limited patent safety. Eli Lilly is aware of that the windfall it’s benefiting from proper now will not final eternally. Even when traders aren’t pondering a decade forward, Eli Lilly is.
This is the reason constructing an infectious illness enterprise is so vital right now. Whereas it appears like a sideline in comparison with GLP-1 medicine, it’s principally Eli Lilly making the most of right now’s success to construct a stronger enterprise over the long run. Whereas there is not any approach to know if any of the three vaccine-focused companies it’s shopping for will flip into huge winners, it’s 100% sure that right now’s GLP-1 success will, sooner or later, fade. Placing one other iron within the hearth with this vaccine funding is solely good monetary stewardship.
Eli Lilly is pricey and centered on staying an business chief
Whereas worth traders will not like Eli Lilly, growth-oriented traders will possible be drawn to it. The GLP-1 story is the core motive to purchase, together with new forms of GLP-1 medicine the corporate has within the works which may be much more efficient than its present choices. Nonetheless, administration’s clear intention to leverage its GLP-1 success to create a extra numerous enterprise might be simply as vital, if no more so. It’s selections like this that result in sustained success over the long run within the drug sector.